<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226470</url>
  </required_header>
  <id_info>
    <org_study_id>2017TALEN-V02</org_study_id>
    <nct_id>NCT03226470</nct_id>
  </id_info>
  <brief_title>Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions</brief_title>
  <official_title>Safety Study of Transcription Activator-like Effector Nucleases T27 and T512 in HPV16-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label and triple cohort study of the safety and efficacy of T27 and T512 to
      possibly treat cervical intraepithelial neoplasia(CIN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent infection with high-risk human papillomavirus (HPVs),especially types 16 and
      18,may lead to cervical intraepithelial neoplasia(CIN).HPVs expresses the oncoproteins E6 and
      E7, both of which play key roles in maintaining viral infection and promoting carcinogenesis.
      Previous studies showed that using designated TALENs (T27 and T512) targeted HPV16 E6 and E7
      produced disruption of HPV16 E6 and E7 DNA, decreased the expression of E6 and E7 proteins,
      and induced cell apoptosis.

      This study will evaluate the safety and efficacy of T27 and T512 in treating HPV Persistency
      and HPV16-positive CIN.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2018</start_date>
  <completion_date type="Anticipated">January 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety-Number of participants with Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants who report adverse events as a measure of safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of HPV16 DNA titers</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Blood samples will be taken at the indicated times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dysplastic cells mearsured by ThinPrep Pap Test</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>From high-grade squamous intraepithelial lesion (HSIL) to Low-grade Squamous Intraepithelial Lesion (LSIL), or from LSIL to negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cervical histological results</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Colposcopy Biopsy will be conducted at the baseline and month 6 on each subject</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Human Papillomavirus-Related Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>T27 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive suppository with T27 at 2 intervals for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T512 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive suppository with T512 at 2 intervals for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T27</intervention_name>
    <description>T27 suppository contain 500 µg of T27 and suppocire.</description>
    <arm_group_label>T27 group</arm_group_label>
    <other_name>TALEN-T27</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T512</intervention_name>
    <description>T512 suppository contain 500 µg of T512 and suppocire.</description>
    <arm_group_label>T512 group</arm_group_label>
    <other_name>TALEN-T512</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HPV16 or HPV18 infection.

          -  Married and fertile, no fertility requirements.

          -  Without administration of hormone in the last six months

          -  Subjects must be meet the ethical requirements and have signed informed consent

        Exclusion Criteria:

          -  Pregnancy and breast feeding

          -  Any bacterial vaginitis

          -  Any Fungal vaginitis

          -  Any sexually transmitted diseases

          -  Active drug or alcohol abuse

          -  Any HPV medications within the past 12 weeks

          -  Allergy to active or non active ingredients in the study of drugs

          -  Cardiac insufficiency

          -  Liver and renal insufficiency

          -  Hypertension and severe complications

          -  Serious illness in past 30 days

          -  Currently participating in another clinical trial or any prior gene therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ding Ma, M.D.</last_name>
    <phone>86-27-83662681</phone>
    <email>dma@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ding Ma, M.D.</last_name>
      <phone>86-27-83662681</phone>
      <email>dma@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, Zhang C, Wang L, Ji T, Liu D, He D, Xia X, Zhu T, Wei J, Wu P, Wang C, Xi L, Gao Q, Chen G, Liu R, Li K, Li S, Wang S, Zhou J, Ma D, Wang H. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest. 2015 Jan;125(1):425-36. doi: 10.1172/JCI78206. Epub 2014 Dec 15.</citation>
    <PMID>25500889</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Head of Cancer Biology center</investigator_title>
  </responsible_party>
  <keyword>Transcription Activator-like Effector Nucleases</keyword>
  <keyword>Human papillomavirus</keyword>
  <keyword>cervical intraepithelial neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

